MesquitaFO, Galindo-FilhoVC, NetoJL, GalvãoAM, FinkJB, Dornelas-de-AndradeA. Scintigraphic assessment of radio-aerosol pulmonary deposition with the Acapella positive expiratory pressure device and various nebulizer configurations. Respir Care, 2014; 59(3):328-333.
2.
KimCS, KangTC. Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease. Am J Respir Crit Care, 1997; 155(3):899-905.
3.
DiotP, PalmerLB, SmaldoneA, DeCelie-GermanaJ, GrimsonR, SmaldoneGC. RhDNase I aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med, 1997; 156(5):1662-1668.
4.
BerlinskiA. In-vitro evaluation of positive expiratory pressure devices attached to nebulizers. Respir Care, 2014; 59(2):216-222.
5.
MogayzelPJJr, NaureckasET, RobinsonKA, MuellerG, HadjiliadisD, HoagJB, et al; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med, 2013; 187(7):680-689.
6.
FlumePA, RobinsonKA, O'SullivanBP, FinderJD, VenderRL, Willey-CourandDB, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care, 2009; 54(4):522-537.
